Pfizer receives European approval for Oncology Biosimilar, RUXIENCE (rituximab) Medical Dialogues Bureau5 April 2020 8:45 AM GMTNew York: Pfizer Inc. has announced that the European Commission (EC) has approved RUXIENCE™ (rituximab), a monoclonal antibody (mAb) and biosimilar...